Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/VTX-801_Pfizer-Investor-Day-1-1024x540.png)
Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/DNA-490376259-1-1024x683.jpg)
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Vivet Therapeutics Announces 2 Abstracts Presentation At 2020 ASGCT Annual Meeting
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/ASGCT-2020.png)
Vivet Therapeutics, a privately held gene therapy biotech company
Happy to share the March 2020 Info Wilson newsletter from ABPWilson!
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/APBW-March-Newsletter.png)
Vivet is very happy to share the March 2020
Vivet presenting during Advanced Therapies 2020 in London
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/Advanced_Therapies_2020.jpg)
Vivet Therapeutics’ CEO, Jean-Philippe Combal
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/nature-communications-vector-logo.png)
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803
Vivet attending Jefferies 2019 London Healthcare Conference
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/03/Jefferies-large.png)
Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during
Vivet Presenting at 2019 World Orphan Drug Congress Europe in Barcelona
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/World-Orphan-Drug-Congress_Vivet.png)
Vivet Therapeutics CEO, Jean-Philippe Combal
VIVET THERAPEUTICS PRESENTING DURING AASLD – THE LIVER MEETING 2019 IN BOSTON
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/AASLD-2019-1024x580.png)
Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO
Vivet Therapeutics Presenting New Results During 2019 ESGCT Annual Congress in Barcelona
![](https://www.vivet-therapeutics.com/wp-content/uploads/2022/05/27th-Annual-Congress-of-the-ESGCT.jpg)
Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy